JP7457704B2 - Ｆｃｒｎ抗体の組成物およびその使用の方法 - Google Patents

Ｆｃｒｎ抗体の組成物およびその使用の方法 Download PDF

Info

Publication number
JP7457704B2
JP7457704B2 JP2021526403A JP2021526403A JP7457704B2 JP 7457704 B2 JP7457704 B2 JP 7457704B2 JP 2021526403 A JP2021526403 A JP 2021526403A JP 2021526403 A JP2021526403 A JP 2021526403A JP 7457704 B2 JP7457704 B2 JP 7457704B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
formulations
lot
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021526403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531346A (ja
JP2021531346A5 (enExample
Inventor
チャン，ジョンリ
セント．ルイス，グレゴリー
ウィリアムズ，エバ
シン，ナリンダー
パティル，シッデシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2021531346A publication Critical patent/JP2021531346A/ja
Publication of JP2021531346A5 publication Critical patent/JP2021531346A5/ja
Application granted granted Critical
Publication of JP7457704B2 publication Critical patent/JP7457704B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2021526403A 2018-07-20 2019-07-19 Ｆｃｒｎ抗体の組成物およびその使用の方法 Active JP7457704B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701467P 2018-07-20 2018-07-20
US62/701,467 2018-07-20
PCT/US2019/042597 WO2020023310A1 (en) 2018-07-20 2019-07-19 Compositions of fcrn antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2021531346A JP2021531346A (ja) 2021-11-18
JP2021531346A5 JP2021531346A5 (enExample) 2022-06-20
JP7457704B2 true JP7457704B2 (ja) 2024-03-28

Family

ID=69180697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526403A Active JP7457704B2 (ja) 2018-07-20 2019-07-19 Ｆｃｒｎ抗体の組成物およびその使用の方法

Country Status (16)

Country Link
US (1) US20210299255A1 (enExample)
EP (1) EP3826641A4 (enExample)
JP (1) JP7457704B2 (enExample)
KR (1) KR20210105872A (enExample)
CN (1) CN113301903A (enExample)
AU (1) AU2019312139B2 (enExample)
BR (1) BR112021001017A2 (enExample)
CA (1) CA3106669A1 (enExample)
CR (1) CR20210088A (enExample)
EA (1) EA202190335A1 (enExample)
IL (1) IL280280B2 (enExample)
JO (2) JOP20210015A1 (enExample)
MX (1) MX2021000790A (enExample)
PH (1) PH12021550096A1 (enExample)
SG (1) SG11202100420UA (enExample)
WO (1) WO2020023310A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64768B1 (sr) 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
IL302516A (en) * 2020-11-06 2023-07-01 Janssen Biotech Inc FCRN antibodies and methods of using them
US20240182598A1 (en) * 2021-04-12 2024-06-06 Momenta Pharmaceuticals, Inc. Compositions and methods for treating pediatric myasthenia gravis
WO2024163894A1 (en) 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
CN116539488B (zh) * 2023-05-11 2023-11-24 中国食品药品检定研究院 一种体外评价生物制品稳定性的方法、系统及设备
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia
WO2025259928A1 (en) * 2024-06-13 2025-12-18 Obi Pharma, Inc. Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof
WO2026083290A1 (en) 2024-10-16 2026-04-23 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009124294A2 (en) 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
JP2015163618A (ja) 2008-11-12 2015-09-10 メディミューン，エルエルシー 抗体製剤
JP2017516848A (ja) 2014-05-23 2017-06-22 アレス トレーディング ソシエテ アノニム 液体医薬組成物
US20180016334A1 (en) 2015-01-30 2018-01-18 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2018023136A1 (en) 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
ES2569409T3 (es) * 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
US20110027267A1 (en) * 2007-11-09 2011-02-03 Anaphore, Inc. Fusion Proteins of Mannose Binding Lectins for Treatment of Disease
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
US9844594B2 (en) * 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
WO2017015622A2 (en) * 2015-07-22 2017-01-26 Scholar Rock, Inc Gdf11 binding proteins and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009124294A2 (en) 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
JP2015163618A (ja) 2008-11-12 2015-09-10 メディミューン，エルエルシー 抗体製剤
JP2017516848A (ja) 2014-05-23 2017-06-22 アレス トレーディング ソシエテ アノニム 液体医薬組成物
US20180016334A1 (en) 2015-01-30 2018-01-18 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
JP6853178B2 (ja) 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
WO2018023136A1 (en) 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SHARMA V. K. et al.，CHAPTER 30 The Formulation and Delivery of Monoclonal Antibodies，Therapeutic Monoclonal Antibodies: From Bench to Clinic，2009年，PART VIII THERAPEUTIC ANTIBODIES，pp.675-709
WANG W. et al.，Journal of Pharmaceutical Sciences，2007年，Vol96 No.1，pp.1-26
WARNE N. W.，European Journal of Pharmaceutics and Biopharmaceutics，2011年，78，pp.208-212

Also Published As

Publication number Publication date
IL280280B2 (en) 2024-11-01
AU2019312139A1 (en) 2021-02-04
WO2020023310A1 (en) 2020-01-30
JP2021531346A (ja) 2021-11-18
CA3106669A1 (en) 2020-01-30
IL280280A (en) 2021-03-25
MX2021000790A (es) 2021-07-21
JOP20210015A1 (ar) 2021-01-19
PH12021550096A1 (en) 2022-03-28
EP3826641A4 (en) 2022-04-20
IL280280B1 (en) 2024-07-01
AU2019312139B2 (en) 2025-02-06
KR20210105872A (ko) 2021-08-27
JOP20210014A1 (ar) 2021-01-19
US20210299255A1 (en) 2021-09-30
CR20210088A (es) 2021-09-02
BR112021001017A2 (pt) 2021-05-04
SG11202100420UA (en) 2021-02-25
EP3826641A1 (en) 2021-06-02
CN113301903A (zh) 2021-08-24
EA202190335A1 (ru) 2021-06-11

Similar Documents

Publication Publication Date Title
JP7457704B2 (ja) Ｆｃｒｎ抗体の組成物およびその使用の方法
JP7442575B2 (ja) Ｆｃｒｎ抗体及びその使用方法
JP7420720B2 (ja) ＦｃＲｎ抗体およびその使用方法
JP7599419B2 (ja) Ｆｃｒｎ抗体組成物
EP4302778A1 (en) Pharmaceutical composition containing anti-tslp antibody
JP2020500195A (ja) アフリベルセプト製剤及びその使用
JP7507160B2 (ja) ヒトｔｒｂｖ９に特異的に結合するモノクローナル抗体
KR102732284B1 (ko) 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
CN101678103A (zh) 抗体制剂
JP2023553209A (ja) 融合タンパク質の医薬製剤
EA046994B1 (ru) КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN119997972A (zh) 抗cd20抗体的药物组合物及其用途
BR112022025721B1 (pt) Formulação estável para anticorpo monoclonal anti-pd-1 recombinante
EA048285B1 (ru) Композиции антител против fcrn
HK40022824A (en) Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240315

R150 Certificate of patent or registration of utility model

Ref document number: 7457704

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150